Journal
BLOOD
Volume 140, Issue 12, Pages 1345-1377Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2022016867
Keywords
-
Categories
Funding
- Deutsche Forschungsgemeinschaft [SFB 1074]
- Australian National Health and Medical Research Council
- Victorian Cancer Agency
- Medical Research Future Fund
- LLS Scholar in Clinical Research award
- Metcalf Family Fellowship
Ask authors/readers for more resources
The 2010 and 2017 editions of the European LeukemiaNet recommendations for AML diagnosis and management are widely recognized. There have been major advances in our understanding of AML, including disease classification updates, improvements in genomic diagnostics, and the development of new therapeutic agents. This update includes a revised genetic risk classification, response criteria, and treatment recommendations.
The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted this update that includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available